ClinicalTrials.gg

Takeda clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,754 studies whose lead sponsor is Takeda or one of 10 companies grouped under it. 86 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 11 registry names, not the registry’s. See them and correct one ↓

Compare Takeda with Bristol-Myers Squibb and Chengdu Kanghong Pharmaceutical Group →

Pipeline: 25 programs

Each counted once: 25 with a study Takeda leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 5 of 11 with the most live studies.

Program
zasocitinibPhase 3 · 13 live · Psoriasis · primary completion Feb 2027☆ Track
elriterceptPhase 3 · 6 live · Myelodysplastic Syndromes · primary completion Feb 2028☆ Track
mezagitamabPhase 3 · 4 live · Purpura, Thrombocytopenic, Idiopathic · primary completion Mar 2028☆ Track
TAK-360Phase 3 · 4 live · Idiopathic Hypersomnia · primary completion Nov 2026☆ Track
TAK-003Phase 3 · 3 live · Dengue · primary completion Apr 2027☆ Track

6 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Takeda’s own registered studies; Takeda’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Takeda’s studies test, most open studies first — 234 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 234; every drug is on its own page, and each page lists its sponsors.

Coming up

47 of Takeda’s studies under way reach primary completion within a year, 12 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 2N’26
  2. 4D
  3. 3J’27
  4. 5F
  5. 3M
  6. 3A
  7. 5M
  8. 6J
  9. 3J
  10. 1A
  11. 5S
  12. 4O
  13. 3N

Add all 47 to your calendar (.ics) → With an account.

All 1,754 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now865%Recruiting 77 · Not yet recruiting 9
  • Under way, not recruiting382%
  • Completed1,37879%
  • Stopped early23714%Terminated 178 · Withdrawn 59
  • Status unknown or other151%No longer available 7 · Approved for marketing 4 · Available 4

Phase

Where

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 10611
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 3226

By the year each study started; 273 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Takeda.

  • Takeda
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1,026 studies
  • Shire
    Acquired — became part of Takeda, Jan 8, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    351 studies →
  • Millennium Pharmaceuticals, Inc.
    Acquired — became part of Takeda, May 9, 2008 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    178 studies →
  • Baxalta now part of Shire
    Acquired — became part of Takeda, Jan 8, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    111 studies →
  • Nycomed
    Acquired — became part of Takeda, Sep 30, 2011 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    31 studies →
  • Movetis
    Acquired — became part of Takeda, Jan 8, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    24 studies →
  • Ariad Pharmaceuticals
    Acquired — became part of Takeda, Feb 16, 2017 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    13 studies →
  • Tigenix S.A.U.
    Acquired — became part of Takeda, Jun 2018 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    11 studies →
  • New River Pharmaceuticals
    Acquired — became part of Takeda, Jan 8, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    6 studies →
  • TiGenix n.v.
    Acquired — became part of Takeda, Jun 2018 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • FerroKin BioSciences, Inc.
    Acquired — became part of Takeda, Jan 8, 2019 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions Takeda leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Show all 52 areas

Studies

Recruiting first, then most recently updated. Showing 50 of 1,754. Browse all 1,754 →